How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset
BioMarin (BMRN) settled patent disputes with Ascendis (ASND) over achondroplasia treatments, agreeing to receive royalties on Yuviwel sales. Under the deal, BMRN will get 20% of U.S. sales and 18% in other regions until 2030. While this reduces competitive risk, Voxzogo's market share could still be pressured. Yuviwel generated €8M in Q2 2026, with further expansion planned. BMRN shares are up 13% YTD, trading at a P/S ratio of 3.06.
How this was made
The 30-second read
Why it matters
The deal provides a new revenue source but does not eliminate competitive risk; market reaction may be muted.
Market read
The settlement is a material corporate action for BioMarin, introducing royalty income while maintaining competitive dynamics.
What to watch
Future competition from BridgeBio's oral therapy could further pressure Voxzogo.
Background
BioMarin's Voxzogo faces competition from Ascendis' Yuviwel; the settlement converts competition into a royalty stream.
Ticker impact
BioMarin announced a settlement with Ascendis granting royalties on Yuviwel sales, creating a new revenue stream.
Potential modest upside for BMRN as the market prices in royalty income.
Royalty rates are significant but depend on Yuviwel's growth; investors may view it as a partial hedge.
Market effects
Achondroplasia treatment market sees increased collaboration, may influence other biotech peers.
US, EU, Brazil, South Korea markets see potential royalty inflows for BioMarin.
Highlights trend of licensing deals to mitigate competition in rare disease space.
Counterpoint
Royalties may be insufficient if Yuviwel captures significant share, limiting upside.
Key entities
- companyBioMarin Pharmaceutical Inc.
US biotech developing Voxzogo for achondroplasia.
- companyAscendis Pharma A/S
Danish biotech launching Yuviwel, now paying royalties to BioMarin.
